Pembrolizumab Biosimilar – Anti-PD1 mAb – Research Grade

Description of Pembrolizumab Biosimilar - Anti-PD1 mAb - Research Grade

General information about Pembrolizumab

Pembrolizumab is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It works by targeting the cellular pathway of proteins found on the body’s immune cells and some cancer cells, known as PD-1/PD-L1. This product is for research use only.

SDS-PAGE for Pembrolizumab Biosimilar - Anti-PD1 mAb

Pembrolizumab Biosimilar - Anti-PD1 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Pembrolizumab Biosimilar - Anti-PD1 mAb binds to CD279 Recombinant Protein in indirect ELISA Assay

Immobilized CD279 Recombinant Protein (cat. No.PX-P4117) at 0.5µg/mL (100µL/well) can bind to Pembrolizumab Biosimilar - Anti-PD1 mAb (cat. No.PX-TA1007) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450